No abstract available
Plain language summary
This nonrandomized controlled trial ancillary study evaluates the survival outcomes associated with corticosteroid use during nivolumab treatment for patients with metastatic renal cell carcinoma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antineoplastic Agents, Immunological* / adverse effects
-
Carcinoma, Renal Cell* / pathology
-
Humans
-
Kidney Neoplasms* / pathology
-
Nivolumab / therapeutic use
-
Retrospective Studies
Substances
-
Nivolumab
-
Antineoplastic Agents, Immunological
-
Adrenal Cortex Hormones